真實世界證據解決方案市場－全球產業規模、佔有率、趨勢、機會和預測，按組件、治療領域、地區和競爭格局分類，2020-2030 年預測

2024年全球真實世界證據解決方案市場規模為29.8億美元，預計2030年將以8.99%的複合年成長率成長至50億美元。全球真實世界證據（RWE）解決方案市場涵蓋了用於收集、分析真實世界資料並從中產生臨床見解的綜合技術和服務，旨在為各種醫療決策提供資訊。該市場的主要促進因素包括：監管機構對藥物研發和核准中RWE的認可度不斷提高、對基於價值的醫療模式的需求日益成長，以及對高效上市後監測的需求不斷擴大。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球真實世界證據解決方案市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按組成部分（理賠資料、臨床設定資料、病患提供的資料、藥局資料、其他組成部分）
  • 依治療領域（腫瘤學、免疫學、神經病學、心血管疾病、其他治療領域）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美真實世界證據解決方案市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲真實世界證據解決方案市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區真實世界證據解決方案市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲真實世界證據解決方案市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲真實世界證據解決方案市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球真實世界證據解決方案市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Clinigen Group PLC
• Icon PLC
• IBM Corporation
• IQVIA Inc.
• Oracle Corporation
• Parexel International
• PerkinElmer Inc.
• Pharmaceutical Product Development (PPD Inc.)
• SAS Institute Inc.
• Syneos Health Inc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Real-World Evidence Solutions Market , valued at USD 2.98 Billion in 2024, is projected to experience a CAGR of 8.99% to reach USD 5.00 Billion by 2030. The Global Real-World Evidence (RWE) Solutions Market encompasses the comprehensive technology and services employed for collecting, analyzing, and generating clinical insights from real-world data to inform diverse healthcare decisions. This market is primarily driven by the increasing regulatory acceptance of RWE in drug development and approvals, the growing demand for value-based care models, and the expanding need for efficient post-market surveillance.

Key Market Drivers

The global Real-World Evidence Solutions Market is fundamentally influenced by increasing regulatory acceptance and the profound shift towards value-based healthcare models. Regulatory bodies globally are progressively integrating real-world evidence into drug development and post-market surveillance. This evolution supports accelerated therapy development by validating outcomes derived from routine clinical practice. According to GlobeNewswire, in August 2024, 82% of drug submissions to the FDA included Real-World Evidence, up from 73% in 2022, demonstrating growing reliance on these solutions for regulatory decision-making. This emphasis by regulators highlights the need for robust real-world data collection and analysis.

Key Market Challenges

The persistent issue of data interoperability and standardization across fragmented global healthcare systems directly impedes the growth of the Global Real-World Evidence Solutions Market. This challenge stems from the diverse formats, terminologies, and governance structures prevalent in real-world data generated across various clinical settings, electronic health record systems, and administrative databases worldwide. Consequently, the seamless aggregation and comprehensive analysis of this disparate data are significantly hindered, demanding extensive manual efforts and complex data harmonization processes. This operational complexity escalates the time and resources required to synthesize meaningful clinical insights, thereby diminishing the efficiency and scalability of real-world evidence initiatives.

Key Market Trends

The integration of artificial intelligence (AI) and machine learning (ML) in Real-World Evidence (RWE) analytics represents a transformative trend, enhancing the ability to derive deep insights from complex datasets. These advanced technologies facilitate more efficient data processing, pattern identification, and predictive modeling, which are crucial for accelerating drug development and optimizing treatment pathways. According to eClinical Solutions' 2024 Industry Outlook, 53% of respondents from clinical operations, data management, and biometrics functions believed AI and ML would have the greatest impact on efficiency and outcomes in 2024, signifying growing industry confidence in these tools. For example, IQVIA announced a collaboration with NVIDIA in January 2025, deploying over 50 AI agents trained on 1.2 billion health records to streamline workflows in life sciences, which demonstrates how AI is directly contributing to faster drug discovery timelines and improved decision-making within the RWE solutions market.

Key Market Players

• Clinigen Group PLC
• Icon PLC
• IBM Corporation
• IQVIA Inc.
• Oracle Corporation
• Parexel International
• PerkinElmer Inc.
• Pharmaceutical Product Development (PPD Inc.)
• SAS Institute Inc.
• Syneos Health Inc.

Report Scope:

In this report, the Global Real-World Evidence Solutions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Real-World Evidence Solutions Market , By Component:

• Claims Data
• Clinical Settings Data
• Patient-Powered Data
• Pharmacy Data
• Other Components

Real-World Evidence Solutions Market , By Therapeutic Area:

• Oncology
• Immunology
• Neurology
• Cardiovascular Disease
• Other Therapeutic Areas

Real-World Evidence Solutions Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Real-World Evidence Solutions Market .

Available Customizations:

Global Real-World Evidence Solutions Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Real-World Evidence Solutions Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, Other Components)
  • 5.2.2. By Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease, Other Therapeutic Areas)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Real-World Evidence Solutions Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Real-World Evidence Solutions Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada Real-World Evidence Solutions Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico Real-World Evidence Solutions Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Real-World Evidence Solutions Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Real-World Evidence Solutions Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France Real-World Evidence Solutions Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Real-World Evidence Solutions Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Real-World Evidence Solutions Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Real-World Evidence Solutions Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Real-World Evidence Solutions Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Real-World Evidence Solutions Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Real-World Evidence Solutions Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan Real-World Evidence Solutions Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea Real-World Evidence Solutions Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Real-World Evidence Solutions Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa Real-World Evidence Solutions Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Real-World Evidence Solutions Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE Real-World Evidence Solutions Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa Real-World Evidence Solutions Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Therapeutic Area

10. South America Real-World Evidence Solutions Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Real-World Evidence Solutions Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia Real-World Evidence Solutions Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina Real-World Evidence Solutions Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Real-World Evidence Solutions Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Clinigen Group PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Icon PLC
• 15.3. IBM Corporation
• 15.4. IQVIA Inc.
• 15.5. Oracle Corporation
• 15.6. Parexel International
• 15.7. PerkinElmer Inc.
• 15.8. Pharmaceutical Product Development (PPD Inc.)
• 15.9. SAS Institute Inc.
• 15.10. Syneos Health Inc.

16. Strategic Recommendations

17. About Us & Disclaimer